Clinical Trial Update: REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) [Phase 2]

View source ↗

Summary

Phase 2 trial REVEAL evaluates retreatment with venetoclax plus acalabrutinib after a limited duration of venetoclax in patients with CLL/SLL; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: CLL/SLL | Phase 2 | Status: RECRUITING